Apel­lis' safe­ty probe in­to eye drug un­earths is­sues with in­jec­tion kits, while side ef­fects re­main 'very rare'

Apel­lis has found a pos­si­ble cul­prit for the safe­ty events af­fect­ing a small num­ber of pa­tients who re­ceived its ge­o­graph­ic at­ro­phy treat­ment — and the in­jec­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER